Genetic variation in caspase-1 as predictor of accelerated progression from mild cognitive impairment to Alzheimer's disease by Pozueta, Ana et al.
 
Genetic variation in caspase-1 as predictor of accelerated progression from 
mild cognitive impairment to Alzheimer´s disease  
 
 
Ana Pozueta, José Luis Vázquez-Higuera, Pascual Sánchez-Juan, Eloy Rodríguez-Rodríguez,  
Coro Sánchez-Quintana, Ignacio Mateo, José Berciano, Onofre Combarros 
 
 
Neurology Service and CIBERNED, “Marqués de Valdecilla” University Hospital 





Key words: Alzheimer´s disease, Early detection, Mild cognitive impairment, APOE, 
Caspase-1, Genetic polymorphism 
 
 
Correspondence to:  Onofre Combarros, Neurology Service, University Hospital “Marqués de 
Valdecilla” (University of Cantabria), 39008-Santander, Spain. Tel. 34-942-202507; Fax: 34-





Sirs: There has been a lot of interest on the detection of predictors of conversion from mild 
cognitive impairment (MCI) to Alzheimer´s disease (AD) using neuroimaging methods, CSF 
biomarkers and cognitive tests [2]. Despite the many genetic studies of AD, there has been 
little research directed toward determining the influence of genetic variation on progression 
from MCI to AD [1, 4]. Variation in the caspase-1 (CASP1) gene has been evaluated in both 
cognitive function in elderly individuals with normal cognition [5] and in predisposition to 
AD [6], but no previous study has specifically explored the association between genetic 
variation in CASP1 and progression from MCI to AD. As a primary goal in this study, we 
investigate APOE ε4 allele and CASP1 (rs580253) polymorphisms in order to predict MCI 
individuals likely to convert to AD in a relatively short follow-up period.  
Between 2007 and 2009, we examined 84 consecutive patients who attended the 
Department of Neurology of University Hospital “Marqués de Valdecilla” (Santander, Spain) 
and that fulfilled the Petersen criteria for amnestic MCI [3]. Patients with MCI were 
longitudinally assessed at 6-month intervals (mean duration of follow-up 26.5 months; SD 
8.1; range 7-37 months); except one MCI-converter patient with a minimal follow-up period 
of 7 months, the rest of our patients were followed up for at least one year to avoid the risk to 
label as MCI-nonconverter subjects who will develop dementia over time. According to their 
Clinical Dementia Rating (CDR) scores during the follow-up period, 50 MCI patients whose 
global CDR score changed from CDR = 0.5 to CDR = 1 were diagnosed as MCI-converters to 
AD (70% women; mean age 76.3 years; SD 5.7; range 60-85 years), and two additional MCI 
patients converted to dementia with Lewy bodies and vascular dementia, respectively; 32 
MCI whose global CDR score remained stable were classified as MCI-nonconverters to AD 
(63% women; mean age 74.8 years; SD 7.0; range 60-86 years). We selected the CASP1 gene 
(rs580253) polymorphism that had been previously related to cognitive function [5]. Blood 
samples were taken after written informed consent had been obtained from the subjects or 
 2 
their representatives. The study was approved by the ethical committee of the University 
Hospital “Marqués de Valdecilla”. Kaplan Meier 
curves and Cox regression model (including APOE status, age and gender) were used to 
assess whether time-to-conversion was associated with CASP1 (rs580253) polymorphism.    
Kaplan-Meier survival analysis (Figure 1), shows the effect of APOE ε4 allele and 
CASP1 (rs580253) T allele on the time-to-conversion to AD in patients with MCI. Survival 
function estimates did not differ significantly between APOE ε4 allele carriers and 
noncarriers. Conversely, the mean time of conversion from MCI to AD was 25.2 months (SD 
9.1) in people with CASP1 (rs580253) T allele (CT and TT genotypes) versus 31.7 months 
(SD 7.4) in CASP1 (rs580253) T allele noncarriers (CC genotype); thus, CASP1 (rs580253) T 
allele accelerated the progression from MCI to AD by an average of 6.5 months (P = 0.009). 
The risk factors of conversion from MCI to AD were analyzed simultaneously with a 
multivariate Cox regression model: CASP1 (rs580253) T allele was significantly associated 
with faster progression from MCI to AD (Hazard Ratio = 1.88, 95% CI 1.02-3.50, P = 0.04), 
whereas age (HR = 0.98, 95% CI 0.93-1.05, P = 0.66), gender (HR = 1.29, 95% CI 0.67-2.49, 
P = 0.44), and  APOE ε4 allele (HR = 1.26, 95% CI 0.67-2.38, P = 0.47) did not reach 
statistical significance.  
The main goal of this study was to analyze the usefulness of genetic variation in APOE 
and CASP1 as biomarkers for progression from MCI to AD in a relatively short period (the 
average follow-up period in this study was 26.5 months). The APOE ε4 allele did not shorten 
time-to-progression from MCI to AD in our series. MCI patients with the APOE ε4 allele 
have been described to be more likely to progress to AD as compared to those without the 
APOE ε4 allele [4], but these studies of AD conversion frequently do not account for time-
dependent progression. According with our results, Barabash et al. [1] did not find that APOE 
ε4 allele was a predictive factor of progression from MCI to AD before 20 months of 
evolution, but these authors observed that Ala/Thr alpha1-antichymotripsin polymorphism 
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was a significative predictor of rapid conversion from MCI to AD over this short follow-up 
period.  Similarly, in the present study CASP1 (rs580253) T allele accelerated the progression 
from MCI to AD (HR = 1.88) and shortened time-to-progression by 6.5 months. In 
conclusion, CASP1 is a modifier gene for the time of progression from MCI to AD, in that it 
might identify patients with MCI who are more likely to rapidly convert to AD during a short 




1. Barabash A, Marcos A, Ancín I, Vázquez-Alvarez B, de Ugarte C, Gil P, Fernández C, 
Encinas M, López-Ibor JJ, Cabranes JA (2009) APOE, ACT and CHRNA7 genes in 
the conversión from amnestic mild cognitive impairment to Alzheimer´s disease. 
Neurobiol Aging 30:1254-1264 
2. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, 
Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ, Alzheimer´s Disease 
Neuroimaging Initiative (2010) Comparing predictors of conversion and decline in 
mild cognitive impairment. Neurology 75:230-238  
3. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor 
M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch 
Neurol 58:1985-1992  
4. Reitz, C, Mayeux R (2010) Use of genetic variation as biomarkers for mild cognitive 
impairment and progression of mild cognitive impairment to dementia. J Alzheimers 
Dis 19:229-251  
5. Trompet S, de Craen AJM, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, Bollen 
ELEM, Buckley BM, Ford I, Gaw A, Macfarlane PW, Packard CJ, Stott DJ, Jukema 
JW, Westendorp RGJ, PROSPER Group (2008) Genetic variation in the interleukin-
 4 
Iβ-converting enzyme associates with cognitive function. The PROSPER study. Brain 
131:1069-1077 
6. Vázquez-Higuera JL, Rodríguez-Rodríguez E, Sánchez-Juan P, Mateo I, Pozueta A, 
Martínez-García A, Frank A, Valdivieso F, Berciano J, Bullido MJ, Combarros O 
(2010) Caspase-1 genetic variation is not associated with Alzheimer´s disease risk. 




Figure 1. Effect of APOE (A) and CASP1 rs580253 (B) genetic variation on survival time 
(Kaplan-Meier analysis) to Alzheimer´s disease (AD) in patients with mild cognitive 
impairment (MCI). The y-axis shows the cumulative proportion of MCI-nonconverters to AD 
for any given follow-up period on the x-axis.  
 
 
 

